Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Helicobacter pylori infection and antibiotic resistance: a WHO high priority?

Nature Reviews Gastroenterology & Hepatology volume 14, pages 383–384 (2017)Cite this article

Subjects

The WHO listed Helicobacter pylori among 16 antibiotic-resistant bacteria that pose the greatest threat to human health. Given the alarmingly high H. pylori antibiotic resistance rates, antibiotic stewardship programmes need to be developed and implemented. Future research should explore provider and systems-level barriers to H. pylori antibiotic susceptibility testing.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Malfertheiner, P. et al. Management of Helicobacter pylori infection — the Maastricht V/Florence consensus report. Gut 66, 6–30 (2017).

    Article  CAS  Google Scholar 

  2. Chey, W. D., Leontiadis, G. I., Howden, C. W. & Moss, S. F. ACG clinical guideline: treatment of Helicobacter pylori infection. Am. J. Gastroenterol. 112, 212–239 (2017).

    Article  Google Scholar 

  3. Shiotani, A., Lu, H., Dore, M. P. & Graham, D. Y. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve. Clin. J. Med. 84, 310–318 (2017).

    Article  Google Scholar 

  4. Graham, D. Y. & Dore, M. P. Helicobacter pylori therapy: a paradigm shift. Expert. Rev. Anti Infect. Ther. 14, 577–585 (2016).

    Article  CAS  Google Scholar 

  5. Graham, D. Y. & Laine, L. The Toronto Helicobacter pylori consensus in context. Gastroenterology 151, 9–12 (2016).

    Article  Google Scholar 

  6. Chen, Q. et al. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am. J. Gastroenterol. 111, 1736–1742 (2016).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

B.N.D. is supported in part by the facilities and resources of the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, and the Center for Innovations in Quality, Effectiveness and Safety (#CIN 13–413), Michael E. DeBakey VA Medical Medical Center, Houston, Texas. She is a current recipient of the K23 Mentored Patient-Oriented Research Career Development Award (K23 MH100965) from the NIH. D.Y.G. is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338, which funds the Texas Medical Center Digestive Diseases Center.

Author information

Authors and Affiliations

  1. VA Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, 77030, Texas, USA

    Bich N. Dang

  2. Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, RM 3A-318B (111D), 2002 Holcombe Boulevard, Houston, 77030, Texas, USA

    David Y. Graham

Authors
  1. Bich N. Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Y. Graham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Y. Graham.

Ethics declarations

Competing interests

D.Y.G. is a consultant for RedHill Biopharma regarding novel H. pylori therapies and has received research support for culture of H. pylori and is the principal investigator of an international study of the use of antimycobacterial therapy for Crohn's disease. He is also a consultant for BioGaia in relation to probiotic therapy for H. pylori infection and for Takeda in relation to H. pylori therapies. B.N.D. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dang, B., Graham, D. Helicobacter pylori infection and antibiotic resistance: a WHO high priority?. Nat Rev Gastroenterol Hepatol 14, 383–384 (2017). https://doi.org/10.1038/nrgastro.2017.57

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.57

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing